PharmaCyte Biotech, Inc. (PMCB)

NASDAQ: PMCB · Real-Time Price · USD

0.5460

-0.0441 (-7.47%)

At close: Aug 10, 2026, 4:00 PM EDT

0.5512

+0.0052 (0.95%)

After-hours: Aug 10, 2026, 7:31 PM EDT

PharmaCyte Biotech Balance Sheet

Financials in millions USD. Fiscal year is May - April.

Millions USD. Fiscal year is May - Apr.

Assets

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Apr '26 Apr 30, 2026	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024	Apr '23 Apr 30, 2023	Apr '22 Apr 30, 2022
Cash & Equivalents	18.6	15.17	50.18	68.04	85.4
Short-Term Investments	18.48	0.37	-	-	-
Cash & Short-Term Investments	37.08	15.54	50.18	68.04	85.4
Cash Growth	138.65%	-69.03%	-26.25%	-20.33%	3778.14%
Other Receivables	0.24	3.7	-	-	-
Total Trade Receivables	0.24	3.7	-	-	-
Other Current Assets	0.1	3.14	0.26	0.11	0.09
Total Current Assets	37.42	22.38	50.44	68.15	85.49
Other Intangible Assets	-	1.55	1.55	3.55	3.55
Long-Term Investments	-	22.47	-	1.57	1.57
Other Long-Term Assets	9.33	10.32	9.46	3.56	3.56
Total Assets	46.75	55.17	59.9	73.28	90.62

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Apr '26 Apr 30, 2026	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024	Apr '23 Apr 30, 2023	Apr '22 Apr 30, 2022
Accounts Payable	0.27	0.4	0.39	0.13	0.21
Accrued Expenses	0.52	2.52	0.74	0.46	0.5
Other Current Liabilities	0.03	-	6.3	-	-
Total Current Liabilities	0.83	2.91	7.42	0.59	0.7
Other Long-Term Liabilities	10.95	0.36	12.97	-	-
Total Long-Term Liabilities	10.95	0.36	12.97	-	-
Total Liabilities	11.77	3.28	20.39	0.59	0.7

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Apr '26 Apr 30, 2026	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024	Apr '23 Apr 30, 2023	Apr '22 Apr 30, 2022
Common Stock	0	0	0	0	0
Treasury Stock	-45.01	-44.61	-42.04	-13.56	-
Additional Paid-in Capital	182.72	181.49	185.33	202.23	201.58
Accumulated Other Comprehensive Income	-0.02	-0.02	-0.02	-0.02	-0.02
Retained Earnings	-104.39	-84.97	-115.63	-115.96	-111.65
Total Common Shareholders' Equity	33.29	51.89	27.65	72.69	89.92
Minority Interest	1.69	-	11.87	-	-
Shareholders' Equity	34.98	51.89	39.51	72.69	89.92
Total Liabilities & Equity	46.75	55.17	59.9	73.28	90.62

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Apr '26 Apr 30, 2026	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024	Apr '23 Apr 30, 2023	Apr '22 Apr 30, 2022
Net Cash (Debt)	37.08	15.54	50.18	68.04	85.4
Net Cash Growth	138.65%	-69.03%	-26.25%	-20.33%	3778.14%
Net Cash Per Share	4.43	2.12	5.24	131.51	165.06
Book Value	33.29	51.89	27.65	72.69	89.92
Book Value Per Share	3.97	7.08	2.89	140.50	173.79
Tangible Book Value	33.29	50.34	26.1	69.14	86.37
Tangible Book Value Per Share	3.97	6.87	2.72	133.63	166.94

SEC Filings: 10-K · 10-Q